Payment overview · 2025
General Payments
$2,463.70
95 reported records · 26 companies
Healthcare provider profile · identity verified
Michael V Sharpe, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1750382669
Verified facts
What the public records show
CMS Open Payments records show Michael V Sharpe, M.D. received $2,463.70 in general payments during 2025 across 95 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1821 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $317.00 | 12.9% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $250.90 | 10.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $215.54 | 8.8% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $170.12 | 6.9% | 2 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $162.40 | 6.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $154.79 | 6.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $154.49 | 6.3% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $136.53 | 5.5% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $118.18 | 4.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.86 | 4.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.04 | 3.4% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $75.27 | 3.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $72.04 | 2.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.12 | 2.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.46 | 1.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.87 | 1.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $43.50 | 1.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.47 | 1.7% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$36.43 | 1.5% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $35.00 | 1.4% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $32.21 | 1.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.59 | 1.3% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.58 | 0.9% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $18.47 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.18 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.66 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,463.70 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $370.33 | 19 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $250.90 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $218.62 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $170.12 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $168.36 | 3 | 2025 |
Source payment records
|
|||||
| ARISTA Normalized: arista |
Device | Davol Inc. | $162.40 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $136.53 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $110.92 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.64 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $75.27 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $72.04 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.46 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.36 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.15 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.87 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $41.47 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.79 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 151 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1821 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 108 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 339 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 80 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 121 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
250 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
339 | 68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
151 | 147 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
339 | 68 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
121 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1821 | 179 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2367 | 532 |
| Eliquis | Apixaban | 1821 | 179 |
| Gabapentin | Gabapentin | 1404 | 243 |
| Amlodipine Besylate | Amlodipine Besylate | 1337 | 284 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1095 | 189 |
| Lisinopril | Lisinopril | 941 | 214 |
| Pantoprazole Sodium | Pantoprazole Sodium | 810 | 173 |
| Tamsulosin Hcl | Tamsulosin Hcl | 743 | 136 |
| Furosemide | Furosemide | 658 | 168 |
| Metformin Hcl | Metformin Hcl | 655 | 151 |
| Carvedilol | Carvedilol | 638 | 141 |
| Metoprolol Tartrate | Metoprolol Tartrate | 636 | 142 |
| Omeprazole | Omeprazole | 618 | 147 |
| Potassium Chloride | Potassium Chloride | 612 | 128 |
| Losartan Potassium | Losartan Potassium | 567 | 116 |
| Clopidogrel | Clopidogrel Bisulfate | 531 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 464 | 108 |
| Levetiracetam | Levetiracetam | 413 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 407 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 404 | 73 |
| Donepezil Hcl | Donepezil Hcl | 397 | 63 |
| Alprazolam | Alprazolam | 385 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 382 | 90 |
| Trazodone Hcl | Trazodone Hcl | 362 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 359 | 92 |
| Mirtazapine | Mirtazapine | 341 | 91 |
| Jardiance | Empagliflozin | 339 | 68 |
| Tramadol Hcl | Tramadol Hcl | 339 | 78 |
| Bumetanide | Bumetanide | 336 | 69 |
| Meloxicam | Meloxicam | 334 | 94 |
| Januvia | Sitagliptin Phosphate | 327 | 36 |
| Memantine Hcl | Memantine Hcl | 320 | 47 |
| Sertraline Hcl | Sertraline Hcl | 313 | 72 |
| Ondansetron Hcl | Ondansetron Hcl | 310 | 104 |
| Simvastatin | Simvastatin | 309 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 301 | 80 |
| Baclofen | Baclofen | 282 | 60 |
| Montelukast Sodium | Montelukast Sodium | 267 | 73 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 266 | 35 |
| Nifedipine Er | Nifedipine | 260 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 256 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 256 | 68 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 253 | 31 |
| Allopurinol | Allopurinol | 251 | 67 |
| Myrbetriq | Mirabegron | 250 | 28 |
| Spironolactone | Spironolactone | 247 | 56 |
| Alendronate Sodium | Alendronate Sodium | 231 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 226 | 52 |
| Latanoprost | Latanoprost | 222 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 221 | 38 |
| Prednisone | Prednisone | 211 | 101 |
| Famotidine | Famotidine | 210 | 50 |
| Doxycycline Hyclate | Doxycycline Hyclate | 209 | 138 |
| Tradjenta | Linagliptin | 206 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 203 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 195 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 49 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 169 | 27 |
| Finasteride | Finasteride | 168 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 166 | 39 |
| Lactulose | Lactulose | 162 | 49 |
| Xarelto | Rivaroxaban | 158 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 155 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 155 | 22 |
| Ezetimibe | Ezetimibe | 154 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 153 | 47 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 151 | 147 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 148 | 103 |
| Atenolol | Atenolol | 145 | 27 |
| Divalproex Sodium | Divalproex Sodium | 143 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 141 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 31 |
| Pregabalin | Pregabalin | 137 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 32 |
| Nystatin | Nystatin | 136 | 70 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 132 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 131 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 37 |
| Valsartan | Valsartan | 131 | 43 |
| Ibuprofen | Ibuprofen | 126 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 122 | 24 |
| Mounjaro | Tirzepatide | 121 | 26 |
| Methocarbamol | Methocarbamol | 118 | 46 |
| Topiramate | Topiramate | 118 | 18 |
| Torsemide | Torsemide | 117 | 33 |
| Clonidine Hcl | Clonidine Hcl | 115 | 38 |
| Entresto | Sacubitril/Valsartan | 110 | 21 |
| Celecoxib | Celecoxib | 108 | 30 |
| Farxiga | Dapagliflozin Propanediol | 108 | 24 |
| Azithromycin | Azithromycin | 107 | 80 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 107 | 15 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 107 | 27 |
| Buspirone Hcl | Buspirone Hcl | 106 | 36 |
| Clonazepam | Clonazepam | 104 | 17 |
| Lorazepam | Lorazepam | 104 | 27 |
| Primidone | Primidone | 103 | 18 |
| Novolog Flexpen | Insulin Aspart | 102 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 102 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 99 | 24 |
| Ceftriaxone | Ceftriaxone Sodium | 98 | 65 |
| Scopolamine | Scopolamine | 98 | 12 |
| Meclizine Hcl | Meclizine Hcl | 97 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 96 | 58 |
| Insulin Aspart Flexpen | Insulin Aspart | 95 | 23 |
| Temazepam | Temazepam | 93 | 21 |
| Lamotrigine | Lamotrigine | 92 | 12 |
| Terazosin Hcl | Terazosin Hcl | 91 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 89 | 35 |
| Fluconazole | Fluconazole | 85 | 56 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 83 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 24 |
| Lansoprazole | Lansoprazole | 81 | 14 |
| Ozempic | Semaglutide | 81 | 23 |
| Linzess | Linaclotide | 80 | 19 |
| Bupropion Xl | Bupropion Hcl | 79 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 78 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 78 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 18 |
| Levemir Flexpen | Insulin Detemir | 77 | 12 |
| Warfarin Sodium | Warfarin Sodium | 76 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 75 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 70 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 20 |
| Albuterol Sulfate | Albuterol Sulfate | 68 | 12 |
| Digoxin | Digoxin | 67 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 18 |
| Trulicity | Dulaglutide | 66 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 65 | 37 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 63 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | suppressed |
| Hydrocortisone | Hydrocortisone | 57 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 35 |
| Diazepam | Diazepam | 54 | suppressed |
| Fenofibrate | Fenofibrate | 54 | 14 |
| Promethazine Hcl | Promethazine Hcl | 54 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 53 | 17 |
| Lidocaine Hcl | Lidocaine Hcl | 53 | 36 |
| Morphine Sulfate Er | Morphine Sulfate | 53 | suppressed |
| Amoxicillin | Amoxicillin | 51 | 35 |
| Carbamazepine | Carbamazepine | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 31 |
| Gemtesa | Vibegron | 50 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Methimazole | Methimazole | 50 | suppressed |
| Restasis | Cyclosporine | 50 | suppressed |
| Clotrimazole | Clotrimazole | 49 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 13 |
| Risperidone | Risperidone | 49 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 49 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 35 |
| Dorzolamide Hcl | Dorzolamide Hcl | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 47 | 12 |
| Glimepiride | Glimepiride | 46 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 45 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 43 | suppressed |
| Lubiprostone | Lubiprostone | 42 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | suppressed |
| Sucralfate | Sucralfate | 42 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 12 |
| Glipizide | Glipizide | 41 | 13 |
| Ketoconazole | Ketoconazole | 40 | 18 |
| Lacosamide | Lacosamide | 40 | suppressed |
| Cyclosporine | Cyclosporine | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 11 |
| Amantadine | Amantadine Hcl | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 12 |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Naloxone Hcl | Naloxone Hcl | 36 | 30 |
| Bupropion Hcl | Bupropion Hcl | 35 | suppressed |
| Erythromycin | Erythromycin Base | 35 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Ertapenem | Ertapenem Sodium | 34 | 15 |
| Levofloxacin | Levofloxacin | 34 | 25 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | 17 |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 32 | suppressed |
| Movantik | Naloxegol Oxalate | 32 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 31 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 31 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 30 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Insulin Aspart | Insulin Aspart | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 21 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 19 |
| Mitigare | Colchicine | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 23 | suppressed |
| Entacapone | Entacapone | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Mirabegron Er | Mirabegron | 23 | 13 |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 22 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 22 | 12 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 22 | 16 |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 11 |
| Leflunomide | Leflunomide | 21 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 21 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Letrozole | Letrozole | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Permethrin | Permethrin | 16 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Ceftazidime | Ceftazidime | 15 | suppressed |
| Motegrity | Prucalopride Succinate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Tivicay | Dolutegravir Sodium | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Cefazolin Sodium-Dextrose | Cefazolin Sodium/Dextrose,iso | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Linezolid | Linezolid | 13 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Byetta | Exenatide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Effer-K | Potassium Bicarbonate/Cit Ac | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Theo-24 | Theophylline Anhydrous | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Transderm-Scop | Scopolamine | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Difluprednate | Difluprednate | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,463.70 · 95 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ARISTA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, ELYXYB - CELECOXIB, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INCEPTIV, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, Natroba, OPSYNVI, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, Spinosad, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, UPTRAVI, VRAYLAR, Veozah, Wegovy, ZEPBOUND, ZTLido | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error